SynthesisMedicine2026
Efficacy and safety of traditional Chinese medicine in treating pediatric IgA vasculitis nephritis: A systematic review and meta-analysis of randomized controlled trials.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIgA vasculitis nephritis (IgAVN) is an important cause of secondary glomerulonephritis and long-term renal morbidity in children. Traditional Chinese medicine (TCM) interventions are widely used for pediatric IgAVN, either alone or combined with Western medicine, but their efficacy and safety remain uncertain. This study evaluated the efficacy and safety of TCM interventions in children with IgAVN.
methodsEight databases were searched from inception to March 7, 2025, for randomized controlled trials comparing TCM interventions with Western medicine alone in children with IgAVN. The primary outcome was the overall clinical effective rate. Secondary outcomes included 24-hour urinary protein excretion, urinary red blood cell count, β2-microglobulin, D-dimer, and adverse events. Meta-analyses were performed using RevMan 5.4. Risk of bias was assessed using the Cochrane risk-of-bias tool, and certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach.
resultsNineteen randomized controlled trials involving 1764 children were included. Compared with Western medicine alone, TCM interventions improved the overall clinical effective rate (risk ratio = 1.20, 95% confidence interval [CI] = [1.15-1.25], P < .00001) and reduced 24-hour urinary protein excretion (standardized mean difference = -0.83, 95% CI = [-1.12 to -0.54], P < .00001) and β2-microglobulin levels (standardized mean difference = -0.54, 95% CI = [-0.70 to -0.38], P < .00001). Sensitivity analyses suggested possible reductions in urinary red blood cell count and D-dimer levels after excluding heterogeneous trials. The incidence of adverse events did not differ significantly between groups (risk ratio = 0.92, 95% CI = [0.60-1.40], P = .70). The certainty of evidence ranged from moderate to very low.
conclusionThe TCM interventions included in this review may provide short-term benefits in clinical response and selected renal-related laboratory outcomes in children with IgAVN, without increasing the observed incidence of adverse events. High-quality randomized trials with standardized outcomes, structured safety monitoring, and longer follow-up are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.